{"nctId":"NCT00219544","briefTitle":"Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.","startDateStruct":{"date":"2005-11"},"conditions":["Neuropathic Pain"],"count":158,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Pregabalin (Lyrica)"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Pregabalin (Lyrica)"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Drug: Pregabalin (Lyrica)"]},{"label":"4","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Pregabalin (Lyrica)","otherNames":[]},{"name":"Pregabalin (Lyrica)","otherNames":[]},{"name":"Pregabalin (Lyrica)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects presenting a diagnosis of peripheral neuropathic pain, defined as pain caused by a lesion of the peripheral nervous system manifesting with sensory symptoms and signs, for at least 6 months at screening.\n* At baseline, subjects must have completed at least 4 daily pain diaries and must have a mean weekly pain score equal or greater than 4.\n\nExclusion Criteria:\n\n* Presence of any of the following diagnoses: Cervical or lumbo-sacral radiculopathy; Operated or non-operated chronic low back pain Carpal tunnel syndrome or any other entrapment-related neuropathic pain (defined as pain associated with focal nerve lesion produced by constriction or mechanical distortion of the nerve, within a fibrous or fibro-osseous tunnel, or by a fibrous band) ; Complex regional pain syndrome (type 1 and 2); Fibromyalgia.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Neuropathic Pain in Subjects With Peripheral Neuropathic Pain Conditions During the Double-blind Phase","description":"Pain score end of Double-Blind treatment = mean of last 7 available pain scores from daily pain diary while on Double-Blind treatment. A Daily Pain Rating Score : 11- point numerical scale ranging from 0 (\"no pain\") to 10 (\"worst possible pain\").","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.84","spread":"0.18"},{"groupId":"OG001","value":"3.62","spread":"0.18"}]}]}]},{"type":"SECONDARY","title":"Weekly Mean Pain Scores During the Single-blind Treatment Phase","description":"Pain score at Week 0 and Week 4, end of single-bind treatment. Mean of last 7 available pain scores from daily pain diary while on single-blind treatment. A Daily Pain Rating Score : 11- point numerical scale ranging from 0 (\"no pain\") to 10 (\"worst possible pain\").","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.29","spread":"1.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.79","spread":"2.11"}]}]}]},{"type":"SECONDARY","title":"Weekly Mean Pain Scores During the Double Blind Treatment Phase","description":"Mean Pain scores for weeks 4, 5, 6, 7, 8 and 9. Mean of last 7 available pain scores from daily pain diary while on single-blind treatment. A Daily Pain Rating Score : 11-point numerical scale ranging from 0 (\"no pain\") to 10 (\"worst possible pain\").","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.68","spread":"1.29"},{"groupId":"OG001","value":"2.49","spread":"1.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.62","spread":"1.48"},{"groupId":"OG001","value":"3.14","spread":"1.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.75","spread":"1.76"},{"groupId":"OG001","value":"3.40","spread":"1.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.53","spread":"1.80"},{"groupId":"OG001","value":"3.20","spread":"1.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.51","spread":"1.59"},{"groupId":"OG001","value":"3.16","spread":"1.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.80","spread":"1.80"},{"groupId":"OG001","value":"3.29","spread":"1.52"}]}]}]},{"type":"SECONDARY","title":"Change in Pain Scores During Double Blind Treatment Phase","description":"Change in Mean Pain score = Mean of last 7 available pain scores from daily pain diary while on single-blind treatment. A Daily Pain Rating Score : 11-point numerical scale ranging from 0 (\"no pain\") to 10 (\"worst possible pain\").","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.15"},{"groupId":"OG001","value":"0.71","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.16"},{"groupId":"OG001","value":"1.05","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.16"},{"groupId":"OG001","value":"0.87","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"0.16"},{"groupId":"OG001","value":"0.83","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"0.15"},{"groupId":"OG001","value":"0.84","spread":"0.17"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With >= 30% Reduction in Mean Pain Score During Single-blind Treatment","description":"Responders = ≥30% reduction in mean pain score at end of single-blind treatment phase compared to weekly mean pain score at baseline. Mean of last 7 available pain scores from daily pain diary while on single-blind treatment. A Daily Pain Rating Score : 11-point numerical scale ranging from 0 (\"no pain\") to 10 (\"worst possible pain\").","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"165","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Pain Score for Responders at End of Single-blind Treatment Phase. Change From Baseline of Mean of Last 7 Available Pain Scores From Daily Pain Diary While on Single-blind Treatment.","description":"Daily Pain Rating Score:11-point numerical scale 0 (\"no pain\") to 10 (\"worst possible pain\"). Responders = ≥30% reduction in mean pain score at end of single-blind treatment phase compared to weekly mean pain score at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.60","spread":"1.32"}]}]}]},{"type":"SECONDARY","title":"Mean Pain Score for Non-responders at End of Single-blind Treatment Phase","description":"Change from baseline of mean of last 7 available pain scores from daily pain diary while on single-blind treatment. Daily Pain Rating Score:11-point numerical scale 0 (\"no pain\") to 10 (\"worst possible pain\"). Non-Responders = \\<30% reduction in mean pain score at end of single-blind treatment phase compared to weekly mean pain score at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.49","spread":"0.95"}]}]}]},{"type":"SECONDARY","title":"Categorized Daily Pain Score","description":"Mean number of days in each pain category. DPRS Daily Pain Rating Score Categories: No pain (score 0), Mild pain (scores 1-3), Moderate pain (scores 4-6), Severe pain (scores 7-10)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"7.6"},{"groupId":"OG001","value":"0.9","spread":"3.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":"12.1"},{"groupId":"OG001","value":"17.4","spread":"11.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"9.5"},{"groupId":"OG001","value":"8.6","spread":"8.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"2.8"},{"groupId":"OG001","value":"1.7","spread":"4.5"}]}]}]},{"type":"SECONDARY","title":"Time to Meaningful Increase in Pain During Double-blind Treatment Phase (Number of Participants)","description":"Number of participants who experienced a meaningful increase in pain also includes participants who took rescue medication for pain due to peripheral neuropathic pain or discontinued from the study .","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Sleep Interference Score","description":"Mean Sleep Interference (SI) score at end of Double-Blind treatment = mean of last 7 available SI scores from daily SI diary while on Double-Blind treatment. Daily SI rating scale (DSIS) consists of an 11-point numerical scale : Zero means \"pain does not interfere with sleep\" and 10 means \"pain completely interferes with sleep.\"","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.81","spread":"0.17"},{"groupId":"OG001","value":"2.52","spread":"0.18"}]}]}]},{"type":"SECONDARY","title":"Weekly Mean Sleep Interference Scores During the Single-Blind Treatment Phase","description":"Sleep Interference (SI) score at Week 0 and Week 4, end of single-bind treatment. Mean of last 7 available SI scores from daily SI diary while on single-blind treatment. Daily SI rating scale (DSIS) consists of an 11-point numerical scale : Zero means \"pain does not interfere with sleep\" and 10 means \"pain completely interferes with sleep.\"","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.80","spread":"2.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.72","spread":"2.42"}]}]}]},{"type":"SECONDARY","title":"Weekly Mean Sleep Interference Scores During the Double Blind Treatment Phase","description":"Mean Sleep Interference scores for weeks 4, 5, 6, 7, 8 and 9. Mean of last 7 available SI scores from daily SI diary while on single-blind treatment. Daily SI rating scale (DSIS) consists of an 11-point numerical scale : Zero means \"pain does not interfere with sleep\" and 10 means \"pain completely interferes with sleep.\"","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.68","spread":"1.57"},{"groupId":"OG001","value":"1.62","spread":"1.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.76","spread":"1.61"},{"groupId":"OG001","value":"2.24","spread":"1.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":"1.81"},{"groupId":"OG001","value":"2.53","spread":"1.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.66","spread":"1.63"},{"groupId":"OG001","value":"2.38","spread":"1.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.59","spread":"1.57"},{"groupId":"OG001","value":"2.36","spread":"1.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.66","spread":"1.74"},{"groupId":"OG001","value":"2.40","spread":"1.86"}]}]}]},{"type":"SECONDARY","title":"Change in Sleep Interference Scores During Double Blind Treatment Phase","description":"Change in Mean SI score: Mean SI score at observation minus mean SI score at week 4. Mean SI Score = mean of last 7 available SI scores from daily SI diary while on single-blind treatment. Daily SI rating scale (DSIS) is 11-point numerical scale : Zero means \"pain does not interfere with sleep\" and 10 means \"pain completely interferes with sleep.\"","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.15"},{"groupId":"OG001","value":"0.59","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.16"},{"groupId":"OG001","value":"0.97","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.16"},{"groupId":"OG001","value":"0.78","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"0.16"},{"groupId":"OG001","value":"0.72","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.15"},{"groupId":"OG001","value":"0.73","spread":"0.17"}]}]}]},{"type":"SECONDARY","title":"Intensity of Neuropathic Pain -Visual Analog Scale (NeP - VAS)","description":"Change in Scale from randomization to Week 9. Scale to measure Neuropathic Pain -Visual Analog Scale (NeP - VAS): the subject places a mark on the VAS scale (0 to 100) where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"2.4"},{"groupId":"OG001","value":"15.9","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Change in Hospital Anxiety and Depression Scale Responses","description":"Mean Change from Randomization in Score from Hospital Anxiety and Depression Scale (HADS): 2 subscales, measuring anxiety (HADS-A)and depression (HADS-D). 7 items in each subscale assessed on a scale of 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). which yields the score ranging 0-21.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.3"},{"groupId":"OG001","value":"1.2","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.3"},{"groupId":"OG001","value":"0.8","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Change in Pain Treatment Satisfaction Scale (PTSS)","description":"Mean Change: score from observation minus score from randomization: PTSS \"Impact\" module of 8-items \\& \"Satisfaction\" module of 6-items; item scores 1-5.\n\nMean score for each module transformed onto scale 0- 100, where score 0 =worst possible response and score 100\n\n=best possible response: Score =\\[(5 - mean non-missing items)\\*100\\]/4.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.96","spread":"2.53"},{"groupId":"OG001","value":"-7.95","spread":"2.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.86","spread":"2.04"},{"groupId":"OG001","value":"-8.35","spread":"2.09"}]}]}]},{"type":"SECONDARY","title":"Patient Global Impression of Change (PGIC) Categories by Number of Subjects","description":"Number of subjects that responded to PGIC Categories. PGIC is a subject-rated instrument that measures change in the subject's overall status on a 7-point scale. Scores range from\n\n1 (very much improved) to 7 (very much worse).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Modified Brief Pain Inventory (mBPI) for Pain Interference or Pain Severity.","description":"Mean Change from Randomization: score at mBPI observation minus score at randomization. mBPI is extent to which pain interferes with daily activities on a 0 (no interference) to 10 (completely interfered) scale.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.19"},{"groupId":"OG001","value":"0.92","spread":"0.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"0.19"},{"groupId":"OG001","value":"1.06","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Change in Euro Quality of Life (EQ-5D) Health State Profile and Visual Analog Scale Components","description":"two components to the EQ-5D: a Health State Profile (scores from five domains are used to calculate the utility score :0 refers to dead and a score of 1 refers to perfect health) and a Visual Analogue Scale (VAS) (0 represents the worst imaginable health state and 100 represents the best imaginable health state)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.02"},{"groupId":"OG001","value":"-0.07","spread":"0.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"1.83"},{"groupId":"OG001","value":"-2.09","spread":"1.89"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["Dizziness","Somnolence","Dry mouth","Peripheral edema","Headache"]}}}